Compare OLMA & IMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OLMA | IMAX |
|---|---|---|
| Founded | 2006 | 1967 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2020 | 1994 |
| Metric | OLMA | IMAX |
|---|---|---|
| Price | $25.06 | $34.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $41.14 | ★ $43.22 |
| AVG Volume (30 Days) | 1.2M | ★ 1.2M |
| Earning Date | 03-17-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.41 |
| EPS | N/A | ★ 0.71 |
| Revenue | N/A | ★ $377,677,000.00 |
| Revenue This Year | N/A | $17.68 |
| Revenue Next Year | N/A | $8.77 |
| P/E Ratio | ★ N/A | $48.64 |
| Revenue Growth | N/A | ★ 9.30 |
| 52 Week Low | $2.86 | $20.48 |
| 52 Week High | $36.26 | $39.98 |
| Indicator | OLMA | IMAX |
|---|---|---|
| Relative Strength Index (RSI) | 44.83 | 43.16 |
| Support Level | $25.83 | $34.30 |
| Resistance Level | $27.86 | $37.86 |
| Average True Range (ATR) | 1.70 | 1.25 |
| MACD | -0.43 | -0.06 |
| Stochastic Oscillator | 24.60 | 33.92 |
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.